[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"University Hospital, Angers\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":636},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,103,0,25,[9,54,81,106,135,163,183,205,225,245,280,306,338,359,378,400,419,444,463,484,507,529,554,579,610],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":42,"lastUpdatePostDateStruct":43,"startDateStruct":46,"completionDateStruct":48,"leadSponsor":50,"locationsCount":53},"100592225","outpatient-versus-inpatient-care-pathway-for-intra-arterial-treatment-of-primary-liver-cancer-choc-100592225",false,"NCT06990659","Outpatient Versus Inpatient Care Pathway for Intra-arterial Treatment of Primary Liver Cancer (CHOC)","CHOC - Implementation and Evaluation of an Ambulatory Care Pathway for Intra-arterial Treatment of Primary Liver Cancer: Study Protocol for a Multicentre Randomised Controlled Hybrid Type 1 Trial Implémentation et évaluation d'un Parcours de Soin Ambulatoire Pour Les Patients traités Par Voie Intra-artérielle d'un Cancer Primitif du Foie : Essai Multicentrique contrôlé randomisé","CHOC","Inclusion Criteria:\n\n* Age ≥ 18 years\n* HCC or iCCA diagnosed according to the criteria of the European Association for the Study of the Liver (2024) or histologically proven.\n* Patient with HCC or iCCA eligible for intra-arterial treatment (transarterial chemoembolization \\[TACE\\] or transarterial radioembolization \\[TARE\\]), with no prior intra-arterial treatment of the same type as the one planned in the trial:\n\n  * no prior TACE for patients included for TACE;\n  * no prior TARE for patients included for TARE. Prior intra-arterial treatment of the other type is allowed (prior TACE before TARE, or prior TARE before TACE). Prior non-intra-arterial treatments are allowed.\n* If TACE is proposed at the multidisciplinary tumour board (RCP):\n\n  * Patient Child-Pugh \\\u003C B8\n  * Single or multiple HCC\n  * Absence of lobar or truncal portal obstruction\n  * Absence of bile duct dilatation\n* If treatment by TARE proposed in RCP:\n\n  * Absence of truncal portal tumor invasion\n  * Uni-lobar tumor invasion (except for centrohepatic iCCA)\n  * Total bilirubin \\\u003C 20 mg\u002Fl (or 35 µmol\u002FL)\n* Patient affiliated to or benefiting from a social security scheme\n* Patient having signed an informed consent form\n\nExclusion Criteria:\n\n* Technical contraindication or morphological elements of predictable technical difficulty\n* Planned combined same-day therapeutic strategies at the index procedure (e.g., TACE combined with percutaneous ablation) are not allowed; sequential (non-same-day) treatments are allowed.\n* Chronic renal insufficiency (Clairance \\\u003C 30 ml\u002Fmin)\n* Known allergy to a contrast agent or chemotherapy agent\n* inability to participate in ambulatory care (inability to understand and follow discharge instructions, lack of reliable telephone access, absence of a responsible accompanying adult for the first night after discharge, or inability to access urgent care in a timely manner if symptoms occur)\n* Patient previously included in the study\n* Patient who, for psychological, social, family or geographical reasons, could not be regularly monitored, patient who, for psychological, social, family or geographical reasons, could not be followed regularly\n* Concomitant disease or severe uncontrolled clinical situation\n* Severe uncontrolled infection\n* Pregnant, breast-feeding or parturient woman\n* Person deprived of liberty by judicial or administrative decision\n* Person under compulsory psychiatric care\n* Person under a legal protection measure\n* Person unable to give consent","ALL","18 Years",{"count":21,"type":22},206,"ESTIMATED","INTERVENTIONAL",[25],"NA","Randomized multicentre trial comparing two care organisations (ambulatory vs conventional inpatient) for patients undergoing transarterial chemoembolization (TACE) or radioembolization (TARE) for primary liver cancer (Hepato Cellular Carcinoma (HCC) or intrahepatic cholangiocarcinoma (iCCA)). Patients are followed for 7 months to assess patient satisfaction, safety and clinical outcomes. A qualitative implementation study and a medico-economic evaluation (cost analysis and 5-years budget impact analysis) are embedded to assess acceptability, adoption, feasability, and sustainability and to inform scaling.",[28,29],"Hepato Cellular Carcinoma (HCC)","Intrahepatic Cholangiocarcinoma",[31,32,33,34,35,36,37,38,39,40],"ambulatory care","hospitalization","Hepato cellular carcinoma","Patient satisfaction","randomized trial","chemoembolization","radioembolization","Intrahepatic","Cholangiocarcinoma","Primary liver cancer","RECRUITING","2026-06-30",{"date":44,"type":45},"2026-07-02","ACTUAL",{"date":47,"type":45},"2025-12-18",{"date":49,"type":22},"2028-12-17",{"name":51,"class":52},"University Hospital, Angers","OTHER_GOV",19,{"id":55,"slug":56,"hasResults":12,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":60,"eligibilityCriteria":61,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":62,"enrollmentInfo":63,"targetDuration":4,"studyType":23,"phases":65,"briefSummary":66,"conditions":67,"keywords":4,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":80},"100641478","post-operative-pain-and-vagal-stimulation-100641478","NCT07659314","Post Operative Pain and Vagal Stimulation","\"Evolution of Postoperative Anal Pain Following Elective Proctological or Rectal Surgery Under the Effect of Transcutaneous Vagal Auricular Stimulation: a Feasibility Study - VAGANAL - Postoperative Pain and Vagal Stimulation\"","VAGANAL","Inclusion Criteria:\n\n* Adult patient\n* Underwent anal or rectal surgery via the transanal route\n* Managed on an outpatient basis or in conventional hospitalization\n* Having signed a consent to participate in the study\n\nExclusion Criteria:\n\n* Patient operated on as an emergency\n* Rectal surgery via abdominal approach or requiring an abdominal approach during the procedure\n* Known epileptic patient\n* Patient with a pacemaker\n* Patient refusing to participate in the study\n* Pregnant, breastfeeding, or laboring woman\n* Patient not affiliated with a social security scheme\n* Person deprived of liberty by judicial or administrative decision\n* Person subject to compulsory psychiatric care - Any contraindication mentioned in the instructions for use of the medical device under investigation\n\nExclusion Criteria:\n\n* Unscheduled conversion from the transanal route to the abdominal route during surgery","120 Years",{"count":64,"type":22},50,[25],"Anorectal surgery is a type of surgery that can cause anal pain, particularly in the context of hemorrhoid surgery or anal fissure surgery. Generally, the period of discomfort related to the pain lasts about two weeks. There is a nerve (the vagus nerve) whose stimulation via a probe placed in the ear can reduce stress and chronic pain. Its ease of use makes it a promising tool for treating pain. Vagal auricular stimulation could be an interesting option in the management of postoperative pain of the anus and rectum. Its efficacy or feasibility in this context has never been evaluated.\n\nThe aim of this study is to evaluate the feasibility in this context and to assess the extend of pain reduction associated with perioperative nerve vagus stimulation by a medical device (Transcutaneous Electrical Nerve Stimulator (TENS ECO Plus)). It is offered to adult patients undergoing transanal anal or rectal surgery on an outpatient or inpatient basis as part of a scheduled procedure.\n\nPatients to be included in the study are selected during the initial pre-operative consultation with the surgeon. Once the surgical indication is confirmed and the patient fulfills the study eligibility criteria, the investigator provides them with oral information about the study. The patient is also given an information sheet (written in language understandable to the patient) and a consent form.\n\nDuring this initial visit, demographic data and information regarding the surgical indication are collected.\n\nStimulation begins two days before surgery (twice daily), followed by stimulation on the morning of surgery, one hour before arrival in the operating room. Successful completion of the stimulation, as well as any complications, are recorded in the patient diary.\n\nOn the day of surgery (day 0), data concerning the procedure and the maximum visual analogue scale (VAS) are collected in the recovery room. Analgesic consumption is also recorded.\n\nOn the evening of the procedure, stimulation is performed and adherence is recorded.\n\nMaximum and mean VAS are collected on postoperative day 1 and then daily in the patient diary for 15 days.\n\nVagus nerve stimulation is performed morning and evening for 15 days. VAS scores, adherence, analgesic consumption, the date of the first bowel movement and its painfulness, as well as any complications related to the stimulation are noted in the patient diary. On day 3 (+\u002F- 2 days) after the procedure, and at the end of the 15-day postoperative period, the patient will be contacted by phone or text message by the investigator team to remind them to complete the notebook.\n\nOn day 30 (+\u002F- 5 days), the patient returns for a follow-up visit. The patient diary and equipment are collected. Complications are recorded, as well as quality of life during the postoperative month (SF-36 form).\n\nFor patients, the expected benefits are significant, as postoperative quality of life is expected to improve through reduced pain. Furthermore, decreasing the use of step II and III analgesics should shorten the recovery period and promote better overall recovery.",[68,69,70],"Rectal Surgery","Pain (Visceral, Somatic, or Neuropathic)","Vagal Nerve Stimulation","NOT_YET_RECRUITING","2026-06-29",{"date":74,"type":45},"2026-07-01",{"date":76,"type":22},"2026-11-09",{"date":78,"type":22},"2028-01-09",{"name":51,"class":52},1,{"id":82,"slug":83,"hasResults":12,"nctId":84,"briefTitle":85,"officialTitle":85,"acronym":86,"eligibilityCriteria":87,"healthyVolunteers":12,"sex":18,"minAge":88,"maxAge":89,"enrollmentInfo":90,"targetDuration":4,"studyType":23,"phases":92,"briefSummary":93,"conditions":94,"keywords":4,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":105},"100492966","screening-in-primary-care-of-advanced-liver-fibrosis-in-nafld-andor-alcoholic-patients-100492966","NCT05699018","Screening in Primary Care of Advanced Liver Fibrosis in NAFLD and\u002For Alcoholic Patients","SOPRANO","Inclusion Criteria:\n\n* NAFLD and\u002For ALD patient defined by at least 1 of the following criteria:\n\n  * Excessive alcohol consumption: higher than 210 g \u002F week (men), or 140 g \u002F week (women)\n  * Type 2 diabetes\n  * at least 2 metabolic factors among BMI higher than or equal to 25 kg \u002F m 2; Elevated blood pressure (antihypertensive drug, or systolic blood pressure higher than or equal to 130mmHg, or diastolic blood pressure higher than or equal to 85mmHg), Dyslipidemia (lipid-lowering drug, or HDL cholesterol lower to 40mg\u002Fdl (men) \u002F 50mg\u002Fdl (women), or triglycerides higher than or equal to150mg\u002Fdl); Hyperferritinemia (higher than upper limit of normal from the laboratory)\n  * Bright liver at ultrasonography without steatosis-inducing drug(systemic corticosteroids, tamoxifen, amiodarone, methotrexate)\n\nFollowing a protocol amendment, the 3 last investigating primary care centres will include NAFLD and\u002For ALD patients according to these updated criteria:\n\n* Excessive alcohol consumption: \\>210 g\u002Fweek in men or \\>140 g\u002Fweek in women,\n* AND\u002FOR type 2 diabetes treated with insulin and\u002For at least two other anti-diabetic treatments,\n* AND with the following stratification:\n\n  30% with excessive alcohol consumption 65% with type 2 diabetes treated with insulin and\u002For at least two other anti-diabetic treatments 5% with both conditions (excessive alcohol consumption, AND type 2 diabetes treated with insulin and\u002For at least two other anti-diabetic treatments)\n* Patient's agreement to have a blood sample collected in a local laboratory participating in the study\n* Subjects covered by or having the rights to medical care assurance\n* Written informed consent obtained from subject\n\nExclusion Criteria:\n\n* Already ongoing specialized follow-up for a chronic liver disease\n* Altered health status with poor short-term prognosis, not compatible with a screening procedure\n* Decompensated cirrhosis (hepatic encephalopathy, jaundice, ascites, variceal bleeding, hepatorenal syndrome)\n* Acute infection\n* Pregnancy, breastfeeding\n* Persons in detention by judicial or administrative decision\n* Person admitted to a health or social establishment for purposes other than research\n* Person subject to a legal protection measure\n* Person unable to express consent","40 Years","80 Years",{"count":91,"type":22},1788,[25],"The primary objective of the SOPRANO study is to compare two blood fibrosis tests, the eLIFT and the FibroMeter, for the screening of advanced liver fibrosis in patients with NAFLD and\u002For ALD from primary care centers.",[95,96,97],"Non-alcoholic Fatty Liver Disease (NAFLD)","Alcoholic Liver Disease (ALD)","Liver Fibrosis","2026-06-26",{"date":42,"type":45},{"date":101,"type":45},"2023-03-13",{"date":103,"type":22},"2026-09-12",{"name":51,"class":52},13,{"id":107,"slug":108,"hasResults":12,"nctId":109,"briefTitle":110,"officialTitle":111,"acronym":112,"eligibilityCriteria":113,"healthyVolunteers":12,"sex":18,"minAge":114,"maxAge":4,"enrollmentInfo":115,"targetDuration":4,"studyType":23,"phases":117,"briefSummary":118,"conditions":119,"keywords":121,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":127,"lastUpdatePostDateStruct":128,"startDateStruct":129,"completionDateStruct":131,"leadSponsor":133,"locationsCount":134},"100523656","evaluation-of-a-prototype-for-an-innovative-room-for-the-elderly-100523656","NCT06098534","Evaluation of a Prototype for an Innovative Room for the Elderly","Evaluation d'un Prototype de Chambre Innovante adaptée au Grand Age","HOSPISENIOR","Inclusion Criteria:\n\n* Age ≥ 75 years\n* Admission in a short-stay geriatric department following initial emergency care department or direct entry from home\n* Hospitalization in single room: Hospi'Senior or conventional\n* Affiliation to a social security scheme\n* Informed consent to participate in the study from the patient or his\u002Fher representative (tutor\u002Fcurator if applicable, or in order of priority a trusted person, the family or a person with whom the person concerned has a close and stable relationship)\n\nExclusion Criteria:\n\n* Contraindication to study participation at the discretion of the medical team\n* Hospitalization for more than 3 days (\\>3 days) in the short-stay geriatric unit\n* Hospitalization in a double room\n* Planned hospitalization\n* Poor understanding of the French language\n* Patient under safeguard of justice","75 Years",{"count":116,"type":22},200,[25],"The Groupement de Coopération Sanitaire des Hôpitaux Universitaires du Grand Ouest (GCS HUGO) (health cooperation group for university hospitals in the west of France), is proposing to improve the quality of geriatric care by modernizing hospital rooms. The GCS HUGO has embarked on a project to co-design a hospital room adapted for the elderly, called \"Hospi'Senior\", with the help of the \"Dépendance et Grand âge\" (Dependency and Old Age) steering committee, made up of experts from HUGO's establishments and experts from several companies.",[120],"Elderly Inpatients",[122,123,124,125,126],"Prototype","Care","Hospital Room","Elderly","Innovation","2026-06-25",{"date":72,"type":45},{"date":130,"type":45},"2023-11-09",{"date":132,"type":22},"2028-02-10",{"name":51,"class":52},5,{"id":136,"slug":137,"hasResults":12,"nctId":138,"briefTitle":139,"officialTitle":140,"acronym":141,"eligibilityCriteria":142,"healthyVolunteers":143,"sex":144,"minAge":19,"maxAge":4,"enrollmentInfo":145,"targetDuration":4,"studyType":23,"phases":147,"briefSummary":148,"conditions":149,"keywords":152,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":127,"lastUpdatePostDateStruct":157,"startDateStruct":158,"completionDateStruct":160,"leadSponsor":162,"locationsCount":80},"100495215","impact-of-time-on-sexual-function-fsfi-score-after-hysterectomy-100495215","NCT05728281","Impact of Time on Sexual Function (FSFI® Score) After Hysterectomy","Recommended Time to Resume Sexual Activity After Hysterectomy: Impact on Sexual Function (FSFI® Score) and Complication Rate ISHYS Study","ISHYS","Inclusion Criteria:\n\n* Patient ≥ 18 years old,\n* Francophone,\n* Sexually active,\n* Receiving a conservative or non-conservative total hysterectomy for benign pathology\\*,\n* Having signed a consent form. All surgical approaches are considered, laparoscopic approach with laparoscopic or vaginal closure, vaginal approach and laparotomy.\n\n  \\*The indications for the procedure selected for this study include:\n* Menometrorrhagia,\n* Fibroids,\n* Adenomyosis,\n* Endometriosis,\n* Pelvic statics disorder,\n* Cervical dysplasia,\n* Endometrial cancer not requiring lymph node dissection or additional treatment.",true,"FEMALE",{"count":146,"type":22},142,[25],"In France, more than 62 000 hysterectomies are performed each year. Female sexual function is the result of multiple psychological, social and physiological factors. There is no information in the current literature about the optimum time between the surgery and the sexual relation resumption. The primary outcome is to assess the impact of advising time between hysterectomy and sexual relation resumption by using FSFI® score. Secondaries outcomes are: to describe and compare post-operative complications in the two groups of the study, to describe the follow-up of the recommendation concerning time between surgery and sexual relation resumption and to describe why this recommendation was not followed. This study is based on 4 questionnaires: FSFI® pre-operative and post-operative, pre-operative questionnaire and post-operative questionnaire. This is a monocentric, comparative, of superiority, randomised and prospective study. Patients are randomised into two groups: sexual relation resumption advised 4 weeks after surgery, or 8 weeks. The inclusion criteria are more than 18 years, francophone, in sexual activity, scheduled for a total hysterectomy for benign indication (menometrorrhagia, fibroma, adenomyosis, endometriosis, pelvic floor disorders, low-grade endometrial cancer), considering vaginal, laparoscopic and abdominal approach, and a written consent. Non-inclusion criteria are illiteracy, cognitive disorders, without social security, deprived liberty by judicial or administrative decision, psychiatric care, patient with legal protection, patient incapable of giving consent. If our conclusions confirmed our hypothesis, it can improve clinical practices by providing additional informations for surgeon and patient, to undergo this surgery as serenely as possible.",[150,151],"Time Between Hysterectomy and Resumption of Sexual Relations","Sexual Function",[153,154,155,156],"benign gynaecological disease","hysterectomy","sexual function","FSFI® score",{"date":98,"type":45},{"date":159,"type":45},"2023-06-05",{"date":161,"type":22},"2027-10-05",{"name":51,"class":52},{"id":164,"slug":165,"hasResults":12,"nctId":166,"briefTitle":167,"officialTitle":167,"acronym":168,"eligibilityCriteria":169,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":170,"targetDuration":4,"studyType":23,"phases":172,"briefSummary":173,"conditions":174,"keywords":4,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":127,"lastUpdatePostDateStruct":177,"startDateStruct":178,"completionDateStruct":180,"leadSponsor":182,"locationsCount":80},"100477601","functional-study-to-indentify-genetic-etiology-of-rare-diseases---origin-100477601","NCT05499091","Functional Study to Indentify Genetic Etiology of Rare Diseases - ORIGIN","ORIGIN","Inclusion Criteria:\n\nPatient :\n\n* Child or adult affected by a rare disease whose molecular functions are not known, or whose pathophysiologic mechanism are not fully understood.\n* Patient included inside the BaMaRa (French rare disease national data bank) database dedicated to the rare diseases.\n* Patient Affiliated to the French social security system.\n* Patient consent form or legal representative consent form obtained.\n\nPatient's parent :\n\n* Parent of a patient affected by a rare disease whose molecular functions are not known, or whose pathophysiologic mechanism are not fully understood.\n* Parent included in the BaMaRa database.\n* Parent affiliated to the French social security system.\n* Parent consent form obtained for himself\u002Fherself.\n\nPatient's brother or sister :\n\n* Brother or sister of a patient (underage or adult) affected by a rare disease whose molecular functions are not known, or whose pathophysiologic mechanism are not fully understood.\n* Brother or sister included in the BaMaRa database.\n* Brother or sister affiliated to the French social security system.\n* Brother or sister consent form obtained for themselves or from their legal representative.\n\nExclusion Criteria:\n\n* Poor understanding of the French language\n* Legal of administrative liberty deprivation\n* Psychiatric force care",{"count":171,"type":22},1200,[25],"Next generation sequencing (NGS) allows some better diagnostic results, particularly, in the rare diseases field. At a twenty five percent rate, those exams highlight some variants which are not yet described in human pathology. The relationship between a variant found inside a candidate gene and a pathology, is able to be confirmed by functional studies at a protein level. This study aims to build a biological collection to feed further functional studies to confirm the relationship between NGS identified variants, and the clinical signs and symptoms.",[175,176],"Rare Diseases","Genetic Disease",{"date":72,"type":45},{"date":179,"type":45},"2022-10-10",{"date":181,"type":22},"2045-10-10",{"name":51,"class":52},{"id":184,"slug":185,"hasResults":12,"nctId":186,"briefTitle":187,"officialTitle":188,"acronym":189,"eligibilityCriteria":190,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":191,"targetDuration":4,"studyType":23,"phases":193,"briefSummary":194,"conditions":195,"keywords":4,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":127,"lastUpdatePostDateStruct":198,"startDateStruct":199,"completionDateStruct":201,"leadSponsor":203,"locationsCount":204},"100429093","a-study-comparing-the-effectiveness-of-endorotor-versus-radiofrequency-in-treating-barretts-esophagus-100429093","NCT04867590","A Study Comparing the Effectiveness of EndoRotor Versus Radiofrequency in Treating Barrett's Esophagus","A Controlled, Randomised Multicenter Study Comparing the Effectiveness of EndoRotor (New Treatment Technique) Versus Radiofrequency (Reference Technique) in Treating Barrett's Esophagus Complicated by Dysplasia","ENDOBARRETT","Inclusion Criteria:\n\n* Adult patients presenting Barrett's esophagus of a size between 2 cm and 6 cm in the height of the longest tonguea with low to high grade dysplasia that is histologically proven or with a superficial non-invasive adenocarcinoma that has been resected a The total height of the BE is evaluated according to the Prague classification, with the height of the circumferential segment between 0 cm (non-circumferential segment) and 6 cm (segment shaped like a full sleeve for 6 cm), referred to as C0 to C6, and the height of the longest tongue between 2 cm and 6 cm (M2- M6).\n* Patients must have signed the consent form in order to participate in the study\n* Patients are pre-included (signature of consent) before the histological confirmation of dysplasiab and\u002For superficial non-invasive adenocarcinoma that allows the patient to be included in the study.\n\nExclusion Criteria:\n\n* Individuals over 85 years old\n* Women who are pregnant, breastfeeding or in labour\n* Individuals in detention through judicial or administrative decision\n* Individuals who are the subject of psychiatric treatment under duress\n* Individuals who are subjects of legal protection measures\n* Individuals who are in no state to give their consent\n* Individuals who do not understand French or do not know how to read\n* Individuals who are not part of a social security program or benefit from such a scheme\n* Those with active peptic and\u002For radiation-induced or complicated esophagitis at the time of treatment\n* Presence of a visible lesion that is suspected to be esophageal cancer confirmed by biopsies\n* Anterior resection of invasive adenocarcinoma using endoscopic mucosal resection (EMR) or endoscopic submucosal dissection (ESD) with invasion of the lateral and\u002For deep margin, adenocarcinoma of poorly differentiated characteristics or sub-mucosal invasion \\> 500µm (pT1b)\n* All preliminary ablation treatments or dilation for esophageal stenosis\n* Significant esophageal stenosis: cannot be passed with a standard gastroscope\n* Presence of esophageal varices or portal hypertension\n* Anticoagulant treatment that cannot be stopped before the intervention (excluding 100 mg maximum per day of aspirin in single-drug treatment) or any haemostasis problems that cannot be corrected\n* Having a contraindication regarding anaesthesia\n* Patients incapable of taking proton pump inhibitors (PPIs) orally.",{"count":192,"type":22},140,[25],"Barrett Esophagus is a common pathology, with an estimated prevalence of 1.6% at risk of progression to precancerous mucosa (low to high grade dysplasia). The incidence of adenocarcinoma on BE is 0.5% per year. In the event of dysplasia or cancer in situ, it is currently recommended at international and particularly European level to eradicate BE. The treatment techniques used to date carry out thermal destruction of the BE, in particular by radiofrequency. Eradication of dysplasia is achieved in 81% to 100% and disappearance of BE in 73% to 87% of cases. It requires an average of 3 destruction sessions. RF does not allow histological analysis after destruction of BE, but the risk of progression to neoplasia is estimated at 7.8\u002F1000 persons per year. This risk could be due to the presence of glands buried in the esophageal mucosa. Indeed, these glands are not destroyed by thermal ablation methods, and remain invisible during endoscopic controls.\n\nA new treatment technique using the Endorotor® system allows mechanical resection of the entire mucosa in one session of treatment. In addition, the cost of these thermal destruction techniques currently limits their wider diffusion. It is therefore legitimate to propose a less expensive and probably more effective alternative technique.",[196,197],"Barrett Esophagus","Dysplasia",{"date":42,"type":45},{"date":200,"type":45},"2022-03-25",{"date":202,"type":22},"2031-07-25",{"name":51,"class":52},17,{"id":206,"slug":207,"hasResults":12,"nctId":208,"briefTitle":209,"officialTitle":209,"acronym":210,"eligibilityCriteria":211,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":212,"targetDuration":4,"studyType":23,"phases":214,"briefSummary":215,"conditions":216,"keywords":4,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":218,"lastUpdatePostDateStruct":219,"startDateStruct":220,"completionDateStruct":222,"leadSponsor":224,"locationsCount":80},"100597790","evaluation-of-the-value-of-ultrasound-measurement-of-stomach-diameter-in-predicting-postoperative-nauseavomiting-100597790","NCT07063069","Evaluation of the Value of Ultrasound Measurement of Stomach Diameter in Predicting Postoperative Nausea\u002FVomiting","EVOL2","Inclusion Criteria:\n\n* Major patient\n* Indication for major abdominal surgery (submesocolic, parietal, left pancreas or liver)\n* Patient affiliated to or benefiting from a social security scheme\n\nNon-inclusion criteria\n\n* Patient refusal to participate in study\n* Need for immediate post-operative ICU stay\n* Surgery performed as an emergency\n* Esophageal, gastric or cephalic pancreatic surgery\n* Person deprived of liberty by judicial or administrative decision\n* Person under compulsory psychiatric care\n\nExclusion Criteria:\n\n* Discharge with nasogastric tube\n* Immediate admission to post-operative intensive care unit",{"count":213,"type":22},150,[25],"The advent of enhanced rehabilitation after surgery has helped to reduce surgical stress, thereby improving postoperative outcomes by reducing the time it takes for patients to recover their transit and autonomy.\n\nDespite this, some 10-30% of patients undergoing abdominal surgery will experience postoperative ileus or nausea\u002Fvomiting. In addition to increasing the length of hospital stay, these complications increase patient discomfort and, above all, the risk of inhalation pneumonitis.\n\nWith the advent of enhanced rehabilitation, patients are receiving less drainage, particularly nasogastric drainage, which is now virtually outlawed in scheduled sub-mesocolic abdominal surgery.\n\nIn a recent international multicenter study of patients undergoing colorectal surgery, the authors reported that less than 10% of patients received a nasogastric tube routinely, and that 20% received it for clinical reasons (before or after nausea\u002Fvomiting). The authors also reported an overall inhalation pneumonitis rate of 4.2%. The authors concluded from this study that nasogastric tubes should not be inserted routinely, but that delay in nasogastric tube insertion was a risk factor for pneumopathy.\n\nAs the onset of postoperative pneumopathy is associated with a risk of mortality, it seems important to predict its risk of onset in order to target patients who could benefit from early nasogastric tube placement.\n\nA recent study carried out in the visceral surgery department of the CHU d'Angers evaluated the evolution of gastric distension. One of the objectives of the ancillary study was to evaluate the interest of the ratio of gastric antrum distension measurement in 2 axes (longitudinal and axial) at D2 postoperative \u002F D preoperative.\n\nAs this was an ancillary study of a preliminary study, the number of events was 12, making it impossible to assert with high power that the appearance of nausea\u002Fvomiting is linked to the ratio described above. An observational study including more patients is therefore needed to confirm this hypothesis before carrying out a randomized controlled trial.",[217],"Patient With Indication for Major Abdominal Submesocolic, Parietal, Left Pancreatic or Liver Surger","2026-06-24",{"date":72,"type":45},{"date":221,"type":45},"2025-08-08",{"date":223,"type":22},"2028-03-19",{"name":51,"class":52},{"id":226,"slug":227,"hasResults":12,"nctId":228,"briefTitle":229,"officialTitle":229,"acronym":230,"eligibilityCriteria":231,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":232,"targetDuration":4,"studyType":23,"phases":234,"briefSummary":235,"conditions":236,"keywords":4,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":218,"lastUpdatePostDateStruct":238,"startDateStruct":239,"completionDateStruct":241,"leadSponsor":243,"locationsCount":244},"100574699","transcriptomic-approach-for-the-identification-and-prioritization-of-genome-variants-in-neurodevelopmental-disorders-with-malformation-100574699","NCT06762678","Transcriptomic Approach for the Identification and Prioritization of Genome Variants in Neurodevelopmental Disorders With Malformation","ATOMICS","Inclusion Criteria :\n\n* children or adult without any age limit, with neurodevelopmental disorders defined by :\n* between 0 and 5 years old with severe developmental delays regarding motor and\u002For language acquisitions, and\u002For social communication disorders,\n* \\> 6 years old with intellectual deficiency whatever the severity (with if available, neuropsychological evaluation), with potential associated manifestations such as epilepsy and\u002For autism, and\u002For behaviour troubles and\u002For attention deficit hyperactivity disorder ;\n* with developmental anomalies and\u002For dimorphism ;\n* without any evidence of clinical diagnosis\n* negative chromosomal microarray and\u002For exome sequencing\n* negative fragile X syndrome\n* skin biopsy feasible or RNA sample extracted from fibroblast culture, available to be used in a research context inside the lab center\n* consent obtained from the participant or, consent from legal representatives for a minor patient or a patient unable to consent\n* participant affiliated to the french security regimen or equivalent\n\nExclusion Criteria:\n\n* Neurodevelopmental disorders with developmental anomaly from non genetic causes or highly evident diagnosis for which a molecular test is available in routine practices and whose the cost is inferior than the cost of the genome and the RNA sequencing\n* unwillingness to participate, from the patient or from the legal representatives\n* Pregnant or lactating women",{"count":233,"type":22},58,[25],"Three million persons in France are impacted by rare diseases. Amid the 7000 different diseases which are identified today, neurodevelopmental disorders are the main symptoms found interesting 35 000 birth every years, according to the French Health Authority. In half of these cases, patients are under 5 years old and a molecular diagnosis is only available in 50% of them, associated with a diagnostic wandering exceeding 5 years for 25% of every patients.\n\nHigh throughput DNA sequencing technologies are powerful tools to elucidate new causative variants. Although the diagnostic yield was refined by DNA-seq, data interpretation and technology limits remain the two major obstacles which still need be overcame. Missing a molecular diagnosis through a genomic approach alone highlight the need to integrate multi-omic approaches such as Ribonucleic Acid sequencing. This sequencing level allows new insight such like the evidence of aberrant gene expression, mono allelic allele expression, or abnormal alternative splicing. It makes possible too, to detect variants which are unable to be found via genome sequencing only.\n\nRecently, a diagnostic performance improvement has been described trough the association of the two technics, i.e. Ribonucleic Acid-seq and genome sequencing, in a context of neuromuscular diseases. However, only few studies were carry out on neurodevelopmental disorders in addition with malformative features. Angers's team demonstrated by the end of 2022, a diagnostic results enhancement by carrying genome sequencing plus Ribonucleic Acid-seq at the same time on patient with previously exome negative analysis. Moreover in 2023, Dekker et al. work shed light on a diagnostic yield improvement via the same analytic schema.\n\nIn face of those first observations, the ATOMICS study aims to evaluate the diagnostic contribution of Ribonucleic Acid-seq paired with genome sequencing in a trio way versus the genome sequencing in a solo way, to identify the find a final diagnosis for patient presenting neurodevelopmental disorders with developmental abnormalities and without an evident diagnosis after chromosome microarray and\u002For exome sequencing analysis.\n\nTo successfully carry out the ATOMICS study, investigators plan to recruit patient in a protocol considered with minimal risk and minimal constraints, to compare Ribonucleic Acid-seq performed on fibroblasts, in addition to genome sequencing in a solo or a trio manner, to trio genome sequencing alone, with the final objective in mind to obtain an etiology diagnostic for a patient presenting with neurodevelopmental disorders and development abnormalities.",[237],"Neurodevelopmental Disorders and Developmental Abnormalities",{"date":72,"type":45},{"date":240,"type":45},"2025-11-04",{"date":242,"type":22},"2028-05-04",{"name":51,"class":52},7,{"id":246,"slug":247,"hasResults":12,"nctId":248,"briefTitle":249,"officialTitle":250,"acronym":251,"eligibilityCriteria":252,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":253,"targetDuration":4,"studyType":23,"phases":255,"briefSummary":257,"conditions":258,"keywords":265,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":272,"lastUpdatePostDateStruct":273,"startDateStruct":274,"completionDateStruct":276,"leadSponsor":278,"locationsCount":279},"100531111","phase-3-rivaroxaban-versus-low-molecular-weight-heparin-in-patients-with-lower-limb-trauma-requiring-brace-or-casting-100531111","NCT06195540","RIVAroxaban Versus Low-molecular Weight Heparin in Patients With Lower Limb Trauma Requiring Brace or CASTing","RIVACAST : RIVAroxaban Versus Low-molecular Weight Heparinin Patients With Lower Limb Trauma Requiring Brace or CASTing","RIVACAST","Inclusion Criteria:\n\n* Patient aged 18 or over ;\n* Consultation in an emergency department of a participating centre;\n* Trauma to the lower limb requiring rigid or semi-rigid orthopaedic immobilisation;\n* Expected duration of orthopaedic immobilisation of at least 2 weeks;\n* TRiP(cast) score ≥ 7 ;\n* Patient affiliated to or benefiting from a social security scheme;\n* Patient with prior informed consent.\n\nExclusion Criteria:\n\n* Patient that have to be hospitalized after emergency department for other reason than lower limb trauma\n* Active bleeding or high risk of bleeding,\n* Known contraindication to rivaroxaban or LMWH;\n* Taking any anticoagulant or antiplatelet agent before the trauma (only antithrombotic authorised: aspirin \\\u003C 325mg\u002Fd);\n* Pregnant or breastfeeding woman;\n* Any factor making 3-month follow-up impossible; 6. Patient subject to a legal protection measure, Imprisonment 7. Participation in any interventional study which modifies patient care or could influence study evaluation criteria",{"count":254,"type":22},1424,[256],"PHASE3","Lower limb trauma requiring immobilization is a very frequent condition that is associated with an increased risk of developing venous thromboembolism (VTE). The TRiP(cast) score has been developed to provide individual VTE risk stratification and help in thromboprophylactic anticoagulation decision. The recent CASTING study had confirmed that patients with a TRiP(cast) score \\\u003C7 have a very low risk of VTE and could be safely manage without prophylactic treatment. Conversely, patients with a score ≥ 7 have a high-risk of VTE and require a prophylactic anticoagulant treatment. Low molecular weight heparins (LMWH) have been shown to be effective in this indication. However, in the CASTING study, the 3-month symptomatic VTE rate was 2.6% in this subgroup despite LMWH prophylactic treatment. This result suggests that LMWH are not sufficiently effective in this particular subgroup of high-risk patients. Direct oral anticoagulants, and in particular rivaroxaban, may be an effective and safe alternative to LMWH. In the PRONOMOS study, comparing LMWH with rivaroxaban in patients who had undergone non-major lower limb surgery, the relative risk of symptomatic VTE was 0.25 (95% CI = 0.09 - 0.75) in favor of rivaroxaban 10mg. No significant increase in bleeding was found. In addition, as LMWH treatment requires subcutaneous daily injections, the use of rivaroxaban may positively impact patients' quality of life as well as being effective in medico-economic terms.\n\nThe aims of this study are to demonstrate that rivaroxaban is at least as effective, easier to use and more efficient than LMWH in patients with trauma to the lower limb requiring immobilisation and deemed to be at risk of venous thromboembolism (TRiP(cast) score ≥ 7). High-risk patients are randomized to receive either rivaroxaban or LMWH. They are followed up at 45 days and 90 days to assess the occurrence of thrombotic events or bleeding, as well as their satisfaction with the treatment received.",[259,260,261,262,263,264],"Venous Thromboembolism","Deep Vein Thrombosis","Pulmonary Embolism","Lower Limb Trauma","Thromboprophylaxis","Immobilisation",[266,267,268,269,270,271],"Emergency department","direct oral anticoagulant","rivaroxaban","Low-Molecular-weight heparin","randomized control trial","Prevent VTE","2026-06-22",{"date":127,"type":45},{"date":275,"type":45},"2024-07-19",{"date":277,"type":22},"2028-11-19",{"name":51,"class":52},37,{"id":281,"slug":282,"hasResults":12,"nctId":283,"briefTitle":284,"officialTitle":285,"acronym":286,"eligibilityCriteria":287,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":288,"targetDuration":4,"studyType":23,"phases":290,"briefSummary":291,"conditions":292,"keywords":4,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":297,"lastUpdatePostDateStruct":298,"startDateStruct":300,"completionDateStruct":302,"leadSponsor":304,"locationsCount":305},"100595132","new-care-pathway-using-automated-dynamic-laximetry-100595132","NCT07028476","New Care Pathway Using Automated Dynamic Laximetry","NPS-LDA - New Care Pathway Using Automated Dynamic Laximetry","NPS-LDA","Inclusion Criteria:\n\n* Patient admitted to an emergency department participating in the study\n* Age ≥ 18 years\n* Consulted following knee trauma and whose clinical examination leads to the suspicion of a partial or complete ACL lesion without bone fracture (supporting radiograph).\n* Signed consent to participate in the study\n* Affiliated to a social security scheme\n\nExclusion Criteria:\n\n* Contraindication to MRI (pacemaker fitted before 2010) or LDA;\n* Indication for emergency or semi-emergency trauma surgery (within 3 weeks: suspected unstable meniscal lesion, fracture, etc.).\n* Impossible follow-up or patient's refusal of follow-up in the investigating center's sports medicine department;\n* Poor understanding of the French language\n* Pregnant (known or suspected pregnancy), breast-feeding or parturient woman;\n* Person deprived of liberty by judicial or administrative decision;\n* Person under compulsory psychiatric care;\n* Person subject to a legal protection measure\n* Person unable to give consent",{"count":289,"type":22},80,[25],"Today, in the event of a knee sprain with suspected cruciate ligament damage, magnetic resonance imaging (MRI) is generally prescribed to confirm or refute the diagnosis and assess its severity. Once the MRI has been performed, the patient's care is organized by the doctor of his or her choice, depending on the diagnosis.\n\nPrevious studies have shown that Automated Dynamic Laximetry (ADL) performs identically to MRI in helping to diagnose a knee sprain as a complementary examination and in assessing its severity. Performing LDA at the start of the patient's care pathway, i.e. immediately after the emergency room visit for a suspected severe sprain, could bring significant benefits by shortening the diagnostic confirmation time and consequently the immobilization period, and by reducing the cost of care compared with the conventional MRI-based care pathway. The new LDA-based care pathway would enable MRI to be reserved for very specific cases, such as the scheduling of surgery for suspected meniscus or osteochondral lesions, as currently recommended by the HAS.",[293,294,295,296],"Knee Sprain","Automated Dynamic Laximetry (ADL)","Care Pathway","MRI","2026-06-17",{"date":299,"type":45},"2026-06-18",{"date":301,"type":45},"2026-03-10",{"date":303,"type":22},"2028-03",{"name":51,"class":52},3,{"id":307,"slug":308,"hasResults":12,"nctId":309,"briefTitle":310,"officialTitle":310,"acronym":311,"eligibilityCriteria":312,"healthyVolunteers":143,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":313,"targetDuration":4,"studyType":23,"phases":315,"briefSummary":316,"conditions":317,"keywords":4,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":297,"lastUpdatePostDateStruct":333,"startDateStruct":334,"completionDateStruct":335,"leadSponsor":337,"locationsCount":80},"100590778","evaluation-of-skin-tests-in-biotherapy-allergies-100590778","NCT06971848","Evaluation of Skin Tests in Biotherapy Allergies","ETCABIO","Inclusion Criteria :\n\n* Patient treated with one of the biotherapies under study (Atezolizumab 1200 mg, Nivolumab 480 mg, Obinutuzumab 100 mg, Durvalumab 1500 mg, Pembrolizumab 200 mg, Daratumumab 1800 mg, Cemiplimab 3500 mg) and who has received at least two injections of the biotherapy without suspected allergic side effects.\n* Subjects covered by or having the rights to medical care assurance\n* Written informed consent obtained from subject\n* If applicable, treatment with corticosteroids and H1 antihistamines by systemic route (IV or oral) which may be discontinued at least one week before performing the tests (Inhaled corticosteroids are allowed).\n\nExclusion Criteria:\n\n* Presence of local or diffuse dermatological lesions (e.g., psoriasis, eczema, ...) that could interfere with the interpretation of skin tests.\n* Poor understanding of the French language\n* Pregnancy, breastfeeding\n* Persons in detention by judicial or administrative decision\n* Person admitted to a health or social establishment for purposes other than research\n* Person subject to a legal protection measure",{"count":314,"type":22},70,[25],"Biotherapies are biological (extracted from an organism or living tissue) or biotechnological drugs used in the treatment of multiple conditions, such as autoimmune inflammatory diseases, cancers, and hematologic diseases. In recent years, these biotherapies have notably emerged in the treatment of cancers and hematologic disorders. As such, most patients with cancers or hematologic diseases will likely receive a biotherapy as part of their care pathway.\n\nThese biotherapies are associated with various side effects, including hypersensitivity or allergic reactions, which are often poorly characterized in clinical trials. These reactions manifest as symptoms without specific dermatologic or allergologic semiology (such as itching, erythema, shortness of breath, sometimes digestive issues, or discomfort, and in some cases, an anaphylactic reaction).\n\nUnlike other treatments, such as antibiotics and neuromuscular blockers, there are currently no guidelines on the concentrations to use in skin tests for biotherapies. We propose conducting prospective clinical research to scientifically establish the concentrations to be used when investigating hypersensitivity to a biotherapy, in line with best practice recommendations for drug skin testing.",[318,319,320,321,322,323,324,325,326,327,328,329,330,331,39,332],"Locally Advanced Cutaneous Squamous Cell Carcinoma of the Head and Neck","Melanoma Neoplasms","Small Cell Bronchial Carcinomas","Bronchial Carcinoma","Pleural Mesothelioma","Hodgkin's Lymphoma","Chronic Lymphocytic Leukemia","Follicular Lymphoma","Myeloma","AL Amyloidosis","Hepatocarcinoma","Colorectal Cancer","Esophageal Squamous Cell Carcinoma","Heart Cancer","Colorectal Adenocarcinoma",{"date":299,"type":45},{"date":297,"type":45},{"date":336,"type":22},"2028-07",{"name":51,"class":52},{"id":339,"slug":340,"hasResults":12,"nctId":341,"briefTitle":342,"officialTitle":343,"acronym":4,"eligibilityCriteria":344,"healthyVolunteers":143,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":345,"targetDuration":4,"studyType":347,"phases":4,"briefSummary":348,"conditions":349,"keywords":4,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":351,"lastUpdatePostDateStruct":352,"startDateStruct":354,"completionDateStruct":356,"leadSponsor":358,"locationsCount":80},"100614122","choice-kerguelen-2--consequences-of-longterm-confinement-on-immunity-in-the-sub-antarctic-islands--follow-up-of-volunteers-on-the-kerguelen-islands-100614122","NCT07275489","CHOICE KERGUELEN 2 : Consequences of Longterm Confinement on Immunity in the Sub-Antarctic Islands : Follow-up of Volunteers on the Kerguelen Islands","Consequences of Longterm Confinement on Immunity in the Sub-Antarctic Islands : Follow-up of Volunteers on the Kerguelen Islands","Inclusion Criteria :\n\n* healthy people aged \\> 18 years\n* Participant affiliated with or benefiting from a social security system\n* Participant has signed informed consent\n* Participant staying as an overwintering member at Kerguelen from November 2025 to November 2026\n* Participant included in the CELREMED research project of the University Hospital of Angers on helathy volunteers in the context of CHOICE Kerguelen 1 protocol\n\nExclusion Criteria:\n\n* age \\\u003C 18 years\n* Pregnant, breastfeeding, or postpartum woman\n* immunocompromised people (primary immunodeficiency, HIV infection or immunosupressive treatment)\n* Person refusing to participate in the study\n* Person with a history of autoimmune disease - -Person deprived of liberty by judicial or administrative decision\n* Person undergoing involuntary psychiatric treatment\n* Person subject to a legal protection measure",{"count":346,"type":22},9,"OBSERVATIONAL","Living for long periods in extreme environments-like Antarctic research stations or space missions-can have a significant impact on human health, especially on the immune system. Scientists have observed that people in such isolated conditions often experience more infections and a reactivation of viruses that usually stay dormant in the body, such as Herpes viruses. These changes affect both parts of the immune system: the rapid-response \"innate\" system and the slower, more specific \"adaptive\" system.\n\nThese immune disruptions may be caused by multiple stressors: ongoing psychological stress, disturbed sleep and light cycles (circadian rhythm disruption), and the challenges of living in confined, isolated, and extreme environments. While space missions and Antarctic overwintering programs have provided some insight into these issues, scientists still lack a detailed understanding of how the immune system adapts-or fails to adapt-over time in such conditions.\n\nTo help fill this gap, the CHOICE Kerguelen 2 study will follow a group of healthy young adults who will spend one year (from November 2025 to November 2026) in Port-aux-Français, a remote French research station on the Kerguelen Islands in the sub-Antarctic. These volunteers are participating in a civic service program and will be living in a highly isolated environment for the duration of their mission. The CHOICE Kerguelen study is conducted in collaboration with the French Polar Institute (IPEV).\n\nThe goal of the study is to collect and store a broad range of biological samples-including blood, saliva, stool, urine, and hair-from these volunteers at four time points during the time of their confinement on the Kerguelent Islands: tevery three months during their stay. These samples will be than analyzed to characterize the immune profiles and intestinal microbiota of the subjects assess eventual viral reactivations and stress biological markers. These analyses will allow to better understand how the immune system reacts to prolonged isolation, and to identify immune profiles that may develop under prolonged stress and limited social contact.\n\nThe long-term aim of this project is not only to improve our understanding of human immunity in extreme environments, but also to inform medical research for people living with chronic illness. By studying healthy individuals placed in physically and mentally challenging environments, scientists can better understand how stress and isolation may weaken immune defenses. The findings may one day help design new approaches to support immune health in vulnerable populations.",[350],"Human Health in Extreme Conditions","2026-06-12",{"date":353,"type":45},"2026-06-15",{"date":355,"type":45},"2025-12-20",{"date":357,"type":22},"2026-12-31",{"name":51,"class":52},{"id":360,"slug":361,"hasResults":12,"nctId":362,"briefTitle":363,"officialTitle":363,"acronym":364,"eligibilityCriteria":365,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":366,"targetDuration":4,"studyType":347,"phases":4,"briefSummary":367,"conditions":368,"keywords":4,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":351,"lastUpdatePostDateStruct":371,"startDateStruct":373,"completionDateStruct":375,"leadSponsor":377,"locationsCount":80},"100595387","petra-pictorial-assessment-of-task-occurrence-and-upper-limb-avoidance-behaviors-100595387","NCT07031791","PETRA: Pictorial Assessment of Task Occurrence and Upper Limb Avoidance Behaviors","PETRA","Inclusion Criteria:\n\n* Adult,\n* Person referred for suspected TDSB\n\nExclusion Criteria:\n\n* Person unwilling to complete questionnaire and participate,\n* Person unable to understand the objectives of the study.",{"count":116,"type":22},"The clinical evaluation of patients suspected of having thoracic brachial outlet syndrome (TBS) is not standardized, as it may be for the lower limbs. Assessment of symptoms and functional impact is based on questionnaires (Disability of the Arm, Shoulder and Hand: DASH, Short Form 36: SF36, Mobility of the Arm and Shoulder: MASC, Thoracic and Upper limb ischemia Pain: TULIP), which are complex to complete, sometimes non-lateralized, and do not take into account the frequency of occurrence of certain gestures or the avoidance behaviours adopted by patients.\n\nFor avoidance behaviors, a recent tool has been proposed in the form of the Avoidance Daily Activities Photo Scale (ADAP shoulder scale). However, this questionnaire has not been translated into French and does not reflect the frequency with which patients are confronted with the different tasks proposed.\n\nThe aim of this study is to test the feasibility of a new questionnaire (PETRA), derived from the ADAP-shoulder scale, which is simple for patients to complete, quick to analyze and calculable directly by the doctor, and suitable for the general population, whether for initial assessment or follow-up.\n\nThe PETRA aims to assess avoidance behaviours in the face of daily tasks, but also the frequency of occurrence of these tasks in order to evaluate a disabling score that weights the avoidance index according to the degree of exposure to the proposed tasks.\n\nThe investigators hypothesize that the PETRA questionnaire could eventually be used routinely.",[369,370,364],"Thoraco-brachial Outlet Syndrome","ADAP-shoulder Scale",{"date":372,"type":45},"2026-06-16",{"date":374,"type":45},"2025-06-27",{"date":376,"type":22},"2027-06",{"name":51,"class":52},{"id":379,"slug":380,"hasResults":12,"nctId":381,"briefTitle":382,"officialTitle":382,"acronym":383,"eligibilityCriteria":384,"healthyVolunteers":12,"sex":18,"minAge":385,"maxAge":386,"enrollmentInfo":387,"targetDuration":389,"studyType":347,"phases":4,"briefSummary":390,"conditions":391,"keywords":4,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":351,"lastUpdatePostDateStruct":393,"startDateStruct":394,"completionDateStruct":396,"leadSponsor":398,"locationsCount":399},"100590801","prevalence-and-description-of-fire-food-induced-immediate-response-of-the-esophagus-in-the-pediatric-population-with-eosinophilic-esophagitis-100590801","NCT06972147","Prevalence and Description of FIRE (Food Induced Immediate Response of the Esophagus) in the Pediatric Population With Eosinophilic Esophagitis","FIREO","Inclusion Criteria:\n\n* Patients over 6 and under 18 years of age at the time of inclusion\n* Follow-up in the allergology unit of Angers University Hospital for eosinophilic esophagitis\n\nExclusion Criteria:\n\n* Patients or legal representative with severe communication or language comprehension difficulties\n* Patients or legal representatives objecting to study participation","6 Years","17 Years",{"count":388,"type":22},40,"1 Day","A new clinical entity of eosinophilic esophagitis, Food Induced Immediate Response of the Esophagus or FIRE, has been described since 2020. Diagnostic criteria are not clearly established. Specific questioning is necessary for differential diagnosis, such as the oro-pharyngeal syndrome notably described in pollinics, or a mechanical blockage strictly speaking linked to esophagitis. The aim is to obtain epidemiological data on this entity.",[392],"Eosinophilic Esophagitis",{"date":353,"type":45},{"date":395,"type":45},"2025-07-01",{"date":397,"type":22},"2026-08-01",{"name":51,"class":52},2,{"id":401,"slug":402,"hasResults":12,"nctId":403,"briefTitle":404,"officialTitle":404,"acronym":405,"eligibilityCriteria":406,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":407,"targetDuration":4,"studyType":23,"phases":409,"briefSummary":410,"conditions":411,"keywords":4,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":351,"lastUpdatePostDateStruct":413,"startDateStruct":414,"completionDateStruct":416,"leadSponsor":418,"locationsCount":399},"100564199","exploratory-study-of-mri-biomarkers-of-nash-100564199","NCT06626074","Exploratory Study of MRI Biomarkers of NASH","IRM-NASH","Inclusion Criteria:\n\n* Patient included in the SNIFF cohort of the Angers hospital where there is a suspicion of NASH requiring a biopsy for which an MRI is requested by a hepatologist as part of the initial assessment of the disease.\n* Adult patient\n* Free, informed and express (oral) consent of the patient to participate in the study\n\nExclusion Criteria:\n\n* Contraindication to MRI\n* Time between the establishment of the Steatosis\u002FNASH status and the MRI greater than 3 months\n* Pregnant, parturient and breastfeeding woman\n* Person deprived of liberty by judicial or administrative decision\n* Person under compulsion to psychiatric care\n* Person subject to a legal protection measure\n* Person not affiliated or not covered by a social security scheme.",{"count":408,"type":22},110,[25],"Metabolic steatosis disease (NAFLD) is a rapidly growing disease in the world, particularly in industrialized countries.\n\nNAFLD is defined by the presence of fatty liver disease. This is a reversible phenomenon that can be estimated by non-invasive means, such as ultrasound. Non-invasive quantification, on the other hand, requires MRI.\n\nNonalcoholic steatohepatitis (NASH) is the aggressive form of the disease that promotes the accumulation of fibrosis in the liver, which can progress to cirrhosis and its complications.\n\nCurrently there is no non-invasive biomarker of NASH and the diagnosis is based solely on liver biopsy.\n\nThere is therefore a need for non-invasive biomarkers of NASH in patients with steatosis to diagnose NASH without the use of liver biopsy.",[412],"Non-alcoholic Fatty Liver Disease NAFLD",{"date":372,"type":45},{"date":415,"type":45},"2025-09-05",{"date":417,"type":22},"2027-09-06",{"name":51,"class":52},{"id":420,"slug":421,"hasResults":12,"nctId":422,"briefTitle":423,"officialTitle":424,"acronym":425,"eligibilityCriteria":426,"healthyVolunteers":12,"sex":18,"minAge":427,"maxAge":19,"enrollmentInfo":428,"targetDuration":4,"studyType":23,"phases":429,"briefSummary":430,"conditions":431,"keywords":433,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":351,"lastUpdatePostDateStruct":438,"startDateStruct":439,"completionDateStruct":441,"leadSponsor":443,"locationsCount":399},"100557118","gait-training-program-with-blood-flow-restriction-in-children-with-cerebral-palsy---embrin-pilot-study-100557118","NCT06533956","Gait Training Program With Blood Flow Restriction in Children With Cerebral Palsy - EMBRIN: Pilot Study","Programme d'Entrainement à la Marche Avec Blood Flow RestrIctioN Chez l'Enfant Avec Paralysie cérébrale - EMBRIN: Etude Pilote","EMBRIN","Inclusion Criteria:\n\n* Patients aged 8 to 18 with bilateral spastic cerebral palsy\n* Patient with functional level II or III according to the Gross Motor Function Classification System (GMFCS)\n* Patient able to assess pain with NRS-11\n* Patient able to walk on a treadmill without body weight support, with or without technical aids\n* Patient able to perform the 10-meter walk test\n* No skin pathology at the pressure cuff application site (eczema, inflammatory scarring, etc.)\n* Patient affiliated to or benefiting from a social security scheme\n* Informed consent, dated and signed by parents or guardians (if a minor) or by the patient (if of age), to participate in the study;\n\nExclusion Criteria:\n\n* Patients who have undergone surgical treatment or intramuscular injections of botulinum toxin in the lower limbs within the last 3 months\n* Patients with a history of arterial hypertension, thrombo-embolic events, thrombophilia or cancer.\n* Patient with insufficient understanding of the French language;\n* Opposition of the patient (child or adolescent);\n* Pregnant, breast-feeding or parturient women;\n* Persons deprived of their liberty by judicial or administrative decision;\n* Persons under compulsory psychiatric care;\n* Persons under legal protection","8 Years",{"count":105,"type":22},[25],"This is a single-center prospective experimental pilot study to assess the feasibility, tolerability and effect of a 10-week gait training program combined with simultaneous blood flow restriction (BFR) on the walking speed of children, aged 8 to 18, with bilateral spastic cerebral palsy.\n\nThe children will receive a 10-week intervention (1 week of habituation without BFR + 9 weeks with BFR) comprising 3 30-minute treadmill sessions per week. At each session, the first 5 minutes will enable a gradual increase in speed, and then the maximum tolerated walking speed will be sought. Maximum speed corresponds to the walking speed maintained by the child for an effort of between 5 and 7 on Borg's 10-point VAS. The rehabilitator will encourage the child to maintain this speed and provide feedback on performance. The BFR setting will maintain an occlusion, at the root level of both lower limbs, of 60% of the total occlusal pressure.\n\nChildren receiving the 10-week EMBRIN program are expected to improve their walking ability and muscular strength, two targets recognized as priorities for individuals with CP by the HAS. In this population, a major limitation of implementing rehabilitation programs is the large amount of practice required to bring about significant changes. This large amount of practice requires a major investment on the part of the individual, as well as significant rehabilitation resources. Muscle-strengthening programs are also particularly repetitive and therefore not very motivating for children. The EMBRIN program could reduce the training load and duration required to impact functional performance in children with CP. It could also help reduce the cost of rehabilitation interventions and reduce physical therapy time for individuals with CP in favor of their social participation.",[432],"Cerebral Palsy",[434,435,436,437],"Cerebral palsy","Blood Flow Restriction","Walking training","Pediatric rehabilitation",{"date":372,"type":45},{"date":440,"type":45},"2024-10-31",{"date":442,"type":22},"2026-10-01",{"name":51,"class":52},{"id":445,"slug":446,"hasResults":12,"nctId":447,"briefTitle":448,"officialTitle":448,"acronym":449,"eligibilityCriteria":450,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":451,"targetDuration":4,"studyType":347,"phases":4,"briefSummary":452,"conditions":453,"keywords":455,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":351,"lastUpdatePostDateStruct":457,"startDateStruct":458,"completionDateStruct":460,"leadSponsor":462,"locationsCount":305},"100534378","normobaric-oxygen-therapy-use-in-critical-limb-ischemia-100534378","NCT06238050","NOrmoBaric Oxygen Therapy Use In Critical Limb ISchemia","NOBILIS","Inclusion Criteria:\n\n* Patient hospitalized in the recruiting centre.\n* Patient fulfilling the clinical and paraclinical criteria (resting TcpO2 values \\\u003C 30mmHg) of the definition of chronic permanent ischemia with or without trophic disorders.\n\nExclusion Criteria:\n\n* Patient suffering from acute or decompensated heart or respiratory failure.\n* Patient suffering from chronic obstructive pulmonary disease (COPD) stage III or IV.\n* Patient with allergies to medical adhesives",{"count":116,"type":22},"Peripheral arteriopathy disease (PAD) affects 1 million people in France. In its most advanced stage: chronic permanent ischemia also called critical ischemia, the prognosis of patients is burdened with a one-year mortality rate of 30%. Chronic permanent ischemia results from a lack of oxygen supply to the microcirculatory network, responsible for tissue death and the development of trophic disorders. In this context, many studies have focused on the contribution of hyperbaric oxygen therapy, however none demonstrates with certainty its beneficial effect with a heavy set-up for teams and patients. Furthermore, it appears that normobaric oxygen therapy could have its place in this context by temporarily restoring a sufficient level of transcutaneous oxygen. However, even if normobaric oxygen therapy is common practice although empirical for some practitioners, no data demonstrates its real interest. The purpose of this study is therefore to report the proportion, in usual practice, of patients with permanent chronic ischemia of the lower limb(s), benefiting from normobaric oxygen therapy, but also to show the interest of the contribution of this therapy in usual comprehensive management of these patients. This is a pilot study, after which, if the hypothesis is confirmed, it may be proposed to carry out a randomized study, on a large scale, in order to validate the use of normobaric oxygen therapy in the context of chronic permanent ischemia.",[454],"Critical Ischemia Limb",[456],"oxygen therapy",{"date":353,"type":45},{"date":459,"type":45},"2025-04-15",{"date":461,"type":22},"2026-12",{"name":51,"class":52},{"id":464,"slug":465,"hasResults":12,"nctId":466,"briefTitle":467,"officialTitle":468,"acronym":469,"eligibilityCriteria":470,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":471,"targetDuration":4,"studyType":347,"phases":4,"briefSummary":473,"conditions":474,"keywords":4,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":478,"lastUpdatePostDateStruct":479,"startDateStruct":480,"completionDateStruct":481,"leadSponsor":483,"locationsCount":80},"100642518","postoperative-analgesia-using-a-perineural-catheter-versus-a-single-nerve-block-in-rearfoot-surgery-100642518","NCT07638514","Postoperative Analgesia Using a Perineural Catheter Versus a Single Nerve Block in Rearfoot Surgery","A Comparative Evaluation of Postoperative Analgesia Using a Perineural Catheter Versus a Single Nerve Block in Rearfoot Surgery","CATHORNOT","Inclusion Criteria:\n\n* Adult patients;\n* Patients with an American Society of Anesthesiologists physical status (ASA score) of 1, 2, or 3;\n* Patients who have undergone hindfoot surgery;\n* Patients capable of completing the questionnaires.\n\nExclusion Criteria:\n\n* Contraindications to regional anesthesia (known hypersensitivity to the local anesthetic, infection at the injection site, uncontrolled neurological condition);\n* Emergency surgery\n* Cognitive impairment;\n* Uncontrolled psychiatric condition;\n* Pregnancy or breastfeeding;\n* Substance abuse;\n* Use of neuroleptics or lithium;\n* Individuals subject to legal guardianship\n* Individuals deprived of liberty by judicial or administrative order\n* Patients who object to the study.",{"count":472,"type":22},60,"Postoperative pain following hindfoot surgery is often severe and can persist for several days. It frequently leads to the use of systemic analgesics, particularly opioids, whose adverse effects are well known. Furthermore, poorly controlled postoperative pain is a recognized independent risk factor for the development of chronic pain.\n\nAmbulatory perineural catheter techniques, already used in our department for hindfoot surgeries, allow for continuous infusion of local anesthetic. They have demonstrated their efficacy in numerous orthopedic surgeries, but data specific to hindfoot surgery remain limited. It therefore seems appropriate to evaluate whether prolonged analgesia via a perineural catheter improves postoperative pain management and promotes functional recovery.\n\nThe study is conducted as a practice evaluation audit. It relies on the collection of data from routine care, without any modification to intraoperative care. This methodology allows for an objective evaluation of the benefits of the perineural catheter compared to a single-injection popliteal sciatic block with local anesthetic, while documenting the frequency and nature of complications associated with the technique (leaks, accidental or intentional catheter removal).",[475,476,477],"Hindfoot Surgery","Analgesia","Perineural Catheter","2026-06-11",{"date":353,"type":45},{"date":397,"type":22},{"date":482,"type":22},"2027-02-07",{"name":51,"class":52},{"id":485,"slug":486,"hasResults":12,"nctId":487,"briefTitle":488,"officialTitle":488,"acronym":489,"eligibilityCriteria":490,"healthyVolunteers":12,"sex":18,"minAge":491,"maxAge":4,"enrollmentInfo":492,"targetDuration":4,"studyType":23,"phases":494,"briefSummary":495,"conditions":496,"keywords":499,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":478,"lastUpdatePostDateStruct":501,"startDateStruct":502,"completionDateStruct":504,"leadSponsor":506,"locationsCount":4},"100642032","allergenic-risk-assessment-of-hemp-seed-100642032","NCT07652853","Allergenic Risk Assessment of Hemp Seed","ARCANA-Clinic","Inclusion Criteria:\n\n* Patients aged 2 years or older\n* Belonging to one or more of the target populations:\n\n  i) Individuals with known or suspected cannabis allergy: Allergy or suspected allergy to hemp seed (HS) defined by A suggestive clinical history of HS allergy and Positive skin prick test (SPT) to HS (≥ 6 mm with erythema exceeding the control papule) and\u002For Basophil activation test (BAT) confirming HS allergy diagnosis OR Allergy or suspected allergy to hemp flower (female or male) defined by a suggestive clinical history of hemp allergy and positive SPT to hemp flower (≥ 6 mm with erythema) and\u002For ImmunoCAP IgE to hemp \\> 0.35 KU\u002FL ii) Individuals allergic to tree nuts (hazelnut or walnut): Allergy to walnut defined by a suggestive clinical history of IgE-mediated walnut allergy and positive SPT to walnut (≥ 8 mm) and IgE to Jug r 1, Jug r 2, or Jug r 3 \\> 1 KU\u002FL and\u002For BAT confirming walnut allergy diagnosis OR Allergy to hazelnut defined by a suggestive clinical history of IgE-mediated hazelnut allergy and positive SPT to hazelnut (≥ 8 mm) and IgE to Cor a 9, Cor a 11, Cor a 14, or Cor a 8 \\> 1 KU\u002FL and\u002For BAT confirming hazelnut allergy diagnosis iii) Individuals allergic to seeds (sesame, flax, pumpkin, sunflower): Allergy to sesame defined by a suggestive clinical history of IgE-mediated sesame allergy and positive SPT to sesame (≥ 6 mm) and\u002For IgE to sesame and\u002For molecular components (Ses i 1 to Ses i 7) \\> 0.35 KU\u002FL and\u002For BAT confirming sesame allergy diagnosis OR Allergy to flaxseed defined by a suggestive clinical history of IgE-mediated flaxseed allergy and positive SPT to flaxseed (≥ 6 mm) and\u002For IgE to flaxseed \\> 0.35 KU\u002FL and\u002For BAT confirming flaxseed allergy diagnosis OR Allergy to pumpkin seed defined by a suggestive clinical history of IgE-mediated pumpkin seed allergy and positive SPT to pumpkin seed (≥ 6 mm) and\u002For IgE to pumpkin seed \\> 0.35 KU\u002FL and\u002For BAT confirming pumpkin seed allergy diagnosis OR Allergy to sunflower seed defined by a suggestive clinical history of IgE-mediated sunflower seed allergy and positive SPT to sunflower seed (≥ 6 mm) and\u002For IgE to sunflower seed \\> 0.35 KU\u002FL and\u002For BAT confirming sunflower seed allergy diagnosis\n* Patients referred to the Allergy Unit at Angers University Hospital (CHU d'Angers) for skin prick testing, either in outpatient consultation or during hospitalization\n* Patients affiliated with or beneficiaries of a social security system\n* Patient or legal representative having signed an informed consent form\n\nExclusion Criteria:\n\n* Pregnant women or women in labor\n* Individuals deprived of liberty by an administrative or judicial decision\n* Individuals undergoing involuntary psychiatric care\n* Adults under a legal protection measure\n* Individuals unable to express their consent\n* Poor understanding of the French language\n* Patients whose skin reactivity prevents the interpretation of the tests","2 Years",{"count":493,"type":22},35,[25],"Cannabis sativa is an annual herbaceous plant from the Cannabaceae family that has been cultivated and consumed by humans for thousands of years. Its main uses include fiber production, seeds for human and animal food, and psychoactive medications. Indeed, cannabis is the most commonly consumed illicit substance among adolescents and poses a major public health issue. Allergic risks associated with cannabis have already been documented.\n\nAt the same time, the consumption of hemp seeds is increasing due to the current agro-food context and the rise of vegan and vegetarian diets. This new food raises questions about its potential allergic risks, especially since the prevalence and severity of food allergies have been steadily increasing over the years. In this context, cases of anaphylaxis related to hemp seeds have already been reported. However, the potential allergic risk associated with hemp seeds remains largely unstudied to date.\n\nSeveral reasons make research into hemp seed allergies relevant:\n\ni) increased exposure to Cannabis sativa in its various forms, with the possibility of finding identical or similar proteins in the seeds; ii) changes in dietary habits, with the vegan trend encouraging the consumption of many seeds, including hemp seeds.",[497,498],"Cannabis","Allergens",[500],"Hemp seed",{"date":297,"type":45},{"date":503,"type":22},"2026-09",{"date":505,"type":22},"2029-03",{"name":51,"class":52},{"id":508,"slug":509,"hasResults":12,"nctId":510,"briefTitle":511,"officialTitle":512,"acronym":513,"eligibilityCriteria":514,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":515,"targetDuration":4,"studyType":347,"phases":4,"briefSummary":517,"conditions":518,"keywords":520,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":478,"lastUpdatePostDateStruct":524,"startDateStruct":525,"completionDateStruct":527,"leadSponsor":528,"locationsCount":305},"100604291","saphir2--simplification-of-physical-activity-assessment-by-rapid-interrogation-100604291","NCT07147608","SAPHIR2 : Simplification of PHysical Activity Assessment by Rapid Interrogation","Simplification of PHysical Activity Assessment by Rapid Interrogation - Phase 2","SAPHIR2","Inclusion criteria:\n\n* Patients referred for a consultation at one of the participating centers\n* Patients over 18 years old with no upper age limit\n\nNon-inclusion criteria:\n\n* Patients with a contra-indication to walking\n* Professional athletes or patients participating in endurance sports competitions\n* Patients refusing to participate in the study\n* Patients unable to understand the objectives or instructions of the study\n\nExclusion criteria:\n\n-Patients with Activ-PAL recordings of less than 3 days",{"count":516,"type":22},118,"A multicentric, non-interventional study using a clinical questionnaire (SAPHIR) and activity monitor (Activ-PAL) to estimate the level of physical activity in the general population.\n\nThis study compares the level of physical activity reported by the SAPHIR questionnaire with the activity recorded by the activity monitor during the same period, in order to determine if the SAPHIR score is able to represent the measured physical activity, in a simple and easily calculable manner.\n\nHypothesis:\n\nThe aim of this work is to propose a new questionnaire that is simple to complete by the patient,quick to analyse and directly calculable by the doctor and adapted to the general population, whether during the initial evaluation or the follow-up.\n\nIndeed, these scores are rarely used outside the context of the prescription of physical activity in specialized centers. Moreover, a tool suited to the constraints of community medicine seems necessary, given the growth of the prescription of physical activity in primary care.\n\nThe idea behind this new questionnaire is to obtain a score ranging from 0 to 100 that can be calculated through simple mental arithmetic, which is not the case for most existing questionnaires, in particular the IPAQ.",[519],"General Population (no Specific Condition or Disease)",[521,522,523],"exercise","sedentary behavior","sports medicine",{"date":353,"type":45},{"date":526,"type":45},"2025-12-19",{"date":376,"type":22},{"name":51,"class":52},{"id":530,"slug":531,"hasResults":12,"nctId":532,"briefTitle":533,"officialTitle":534,"acronym":535,"eligibilityCriteria":536,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":537,"targetDuration":4,"studyType":23,"phases":538,"briefSummary":539,"conditions":540,"keywords":4,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":546,"lastUpdatePostDateStruct":547,"startDateStruct":549,"completionDateStruct":551,"leadSponsor":553,"locationsCount":4},"100643194","a-study-of-the-determinants-of-neurological-outcomes-in-patients-with-acute-respiratory-distress-syndrome-100643194","NCT07629973","A Study of the Determinants of Neurological Outcomes in Patients With Acute Respiratory Distress Syndrome","Etude Des déterminants de l'évolution NEUrologique Des Patients Ayant présenté un Syndrome de Détresse Respiratoire aiguë","NEURDS","Inclusion Criteria:\n\n* Adult patient\n* Patient admitted to the intensive care unit less than 48 hours ago\n* Patient diagnosed with mild, moderate or severe ARDS according to the Berlin classification based on the PaO₂\u002FFiO₂ ratio, with a minimum PEEP set at 5 cmH₂O (16), of pulmonary aetiology:\n\n  * Mild ARDS: 200 \\\u003C PaO₂\u002FFiO₂ \\\u003C 300 mmHg\n  * Moderate ARDS: 100 \\\u003C PaO₂\u002FFiO₂ \\\u003C 200 mmHg\n  * Severe ARDS: PaO₂\u002FFiO₂ \\\u003C 100 mmHg\n* Patients fitted with an oesophageal pressure measurement catheter (Nutrivent, Sidam, San Giacomo Roncole, Italy)\n* Patients registered with or covered by a social security scheme\n* Free and informed consent from the patient or a trusted relative (where the patient is unable to give consent).\n\nExclusion Criteria:\n\n* Patients with a history of central nervous system disorders resulting in cognitive impairment\n* Patients on ECMO\n* Patients admitted for symptomatic central nervous system disorders\n* Patients admitted for acute respiratory distress syndrome following cardiorespiratory arrest.\n* Patients being treated for a psychiatric condition, chronic heavy drinkers, or those undergoing long-term treatment with benzodiazepines, antidepressants or antipsychotics.\n* Pregnant, breastfeeding or labouring patients\n* Individuals subject to a legal protection order\n* Individuals receiving compulsory psychiatric care\n* Individuals deprived of their liberty by judicial or administrative decision",{"count":213,"type":22},[25],"Acute respiratory distress syndrome (ARDS) is characterized by pathological pulmonary edema caused by direct or indirect damage to the alveolar-capillary membrane.\n\nIts management relies on etiological treatment, invasive mechanical ventilation, and the use of sedatives and neuromuscular blockers, depending on the patient's condition.\n\nImprovements in patient care have led to an improved prognosis. However, in-hospital mortality remains high (between 35% and 45%). Notably, morbidity among surviving patients is very high and is largely dominated by neuropsychological sequelae. Attention and executive function disorders, confusion, disorientation, or memory impairment are thus found in 70 to 100% of patients following ARDS. These disorders are still present in 46 to 80% of surviving patients one year after ARDS and in 20% of them five years later.\n\nAlthough essential to treatment, mechanical ventilation carries a risk of significant complications. Beyond the risk of infection and complications related to sedation and neuromuscular blockade, the use of mechanical ventilation is associated with a risk of ventilator-induced lung injury (VILI).\n\nThe use of so-called protective ventilation reduces the risk of VILI and improves patient outcomes. However, analysis of relevant physiological parameters shows that the risk of VILI may still exist even when ventilator settings comply with recommendations and the concept of protective ventilation. Driving pressure (which represents Strain) is a good marker of VILI; it represents the distension of the lung with each breath relative to the initial lung volume. Values above 14 cmH₂O are associated with high mortality in patients with ARDS. Inspiratory transpulmonary pressure represents Stress-that is, the pressure that distends the alveoli at the end of inspiration-and is also associated with the risk of VILI. Finally, mechanical power represents the amount of energy delivered to the lung by the ventilator and has been validated as a marker of VILI. The advantage of mechanical power over the other indices described is that it incorporates all components that can lead to VILI.\n\nAmong the various sources of neurological damage during ARDS, inflammatory processes appear to play a major role. Numerous inflammatory mediators (TNF-α, IL-6, IL-8, IL-1β) are secreted during ARDS, and animal studies have demonstrated a link between inflammation and hippocampal damage. Furthermore, cerebral ischemic lesions, exacerbated by systemic inflammation and endothelial activation leading to coagulation activation with thrombus formation, may also contribute to the development of cognitive impairments.\n\nIn addition to the inflammatory processes associated with ARDS, mechanical ventilation itself may have a significant impact on neuroinflammatory damage. Recently, the term \"ventilator-associated brain injury\" (VABI) has been proposed to describe these secondary neurological lesions induced by mechanical ventilation. Studies in mouse and pig models have demonstrated a relationship between the dose and duration of VILI, apoptosis, neuroinflammation, and neuronal damage. An animal study in mice also showed an association between the duration of mechanical ventilation and the onset of cognitive impairments.\n\nDuring brain injury, proteins and neurotransmitters are released and serve as biomarkers of brain damage. Elevated plasma levels of S100B protein indicate astrocyte damage caused by traumatic, anoxic-ischemic, or inflammatory mechanisms. It correlates with neurological prognosis following cardiac arrest, in ischemic or hemorrhagic strokes, in neurodegenerative diseases, and in patients with traumatic brain injury.\n\nClinical studies have shown a negative correlation between elevated S100B protein levels, the MoCA (Montreal Cognitive Assessment) score, and the MMSE (Mini-mental state evaluation ) in patients with OSA (Obstructive Sleep Apnea) or COPD (chronic obstructive pulmonary disease), respectively, indicating an association between this protein and cognitive impairment.\n\nThe investigators therefore hypothesize that mechanical ventilation associated with high mechanical power is linked to a significant risk of brain injury, reflected by elevated serum S100B protein levels and the presence of neurocognitive disorders long after ARDS.",[541,542,543,544,545],"Acute Respiratory Distress Syndrome (ARDS)","s100b","Mechanical Power","Ventilator Induced Lung Injury","Transpulmonary Pressure","2026-06-09",{"date":548,"type":45},"2026-06-10",{"date":550,"type":22},"2026-10-17",{"date":552,"type":22},"2029-10-23",{"name":51,"class":52},{"id":555,"slug":556,"hasResults":12,"nctId":557,"briefTitle":558,"officialTitle":559,"acronym":560,"eligibilityCriteria":561,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":562,"targetDuration":4,"studyType":23,"phases":564,"briefSummary":565,"conditions":566,"keywords":569,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":546,"lastUpdatePostDateStruct":573,"startDateStruct":574,"completionDateStruct":576,"leadSponsor":577,"locationsCount":578},"100602165","prospexpo--study-of-the-associations-between-hepatocellular-carcinoma-and-chemical-and-psychosocial-environmental-exposome-100602165","NCT07119957","ProspEXPO : Study of the Associations Between Hepatocellular Carcinoma and Chemical and Psychosocial Environmental EXPOsome","ProspEXPO : PROSPective Study of the Associations Between Hepatocellular Carcinoma and Chemical and Psychosocial Environmental EXPOsome","ProspEXPO","Inclusion Criteria:\n\n* Presence of metabolic and\u002For alcoholic steatotic liver disease, as defined by the new nomenclature (MASLD, ALD, or mixed MetALD)\n* Liver biopsy performed (less than 2 months ago) or planned as part of treatment for diagnosis of cirrhosis (\"Control\" group without HCC) or diagnosis of HCC on cirrhosis (\"Case\" group)\n* Patient affiliated to or benefiting from a social security scheme\n* Patient having signed an informed consent to participate in the study (bio-collection)\n\nExclusion Criteria:\n\n* Causes of chronic liver disease other than MASLD, ALD, or MetALD\n* Decompensation of cirrhosis in the two years prior to inclusion (ascites, hepatic encephalopathy, gastrointestinal variceal hemorrhage, liver failure, hepatorenal syndrome)\n* For the \"Control\" group: history of hepatocellular carcinoma\n* Pregnant, breast-feeding or parturient women\n* Persons deprived of liberty by judicial or administrative decision",{"count":563,"type":22},300,[25],"The aim of the study is to build up a bio-collection of biological samples from patients with cirrhosis. Further work using this bio-collection will permit to describe the influence of different exposome factors (nutrition, physical activity, socio-demographic conditions, tobacco, alcohol, pollutants) on the occurrence of the main type of liver cancer (called HCC).\n\nIndeed, in the vast majority of cases, HCC develops within cirrhosis, and the factors that precipitate the progression of cirrhotic patients to HCC remain largely unknown.",[567,568],"Cirrhoses, Liver","Carcinoma Liver",[570,571,572],"Liver Cirrhosis","HepatoCellular Carcinoma (HCC)","Exposome",{"date":548,"type":45},{"date":575,"type":45},"2025-12-17",{"date":505,"type":22},{"name":51,"class":52},4,{"id":580,"slug":581,"hasResults":12,"nctId":582,"briefTitle":583,"officialTitle":583,"acronym":584,"eligibilityCriteria":585,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":586,"targetDuration":4,"studyType":23,"phases":588,"briefSummary":589,"conditions":590,"keywords":595,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":603,"lastUpdatePostDateStruct":604,"startDateStruct":606,"completionDateStruct":607,"leadSponsor":609,"locationsCount":134},"100639121","strategies-for-weaning-from-external-ventricular-drainage-100639121","NCT07630051","Strategies for Weaning From External Ventricular Drainage","SEVDVE2","Inclusion Criteria:\n\n* Adult patient (≥18 years)\n* Admitted to critical care for non-traumatic subarachnoid hemorrhage for less than 3 days\n* First external ventricular drain inserted within the last 3 days for hydrocephalus and\u002For intracranial hypertension\n* Patient consent, or consent from a relative, or inclusion under emergency inclusion procedure\n* Patient affiliated to or beneficiary of a social security scheme\n\nExclusion Criteria:\n\n* Moribund patient or patient with established treatment limitation\u002Fwithdrawal decisions\n* Patient with a pre-existing ventriculoperitoneal or ventriculoatrial shunt\n* Patient with chronic hydrocephalus\n* Pregnant, lactating, or parturient woman\n* Person deprived of liberty by judicial or administrative decision\n* Person under involuntary psychiatric care\n* Person under a legal protection measure\n* Concurrent participation in another study involving external ventricular drainage management",{"count":587,"type":22},170,[25],"External ventricular drainage is frequently used in neurocritical care, particularly in patients admitted for non-traumatic subarachnoid hemorrhage who develop hydrocephalus and\u002For intracranial hypertension. While external ventricular drainage is often initially lifesaving, its prolonged maintenance is associated with complications, especially infections and prolonged hospital length of stay. There is currently no consensus on the optimal weaning strategy. Two approaches are used in routine practice: direct clamping (the external ventricular drain is closed as soon as weanability criteria are met) and gradual weaning (the external ventricular drain level is progressively raised before final clamping). No randomized controlled trial has yet demonstrated the superiority of one strategy over the other in patients with non-traumatic subarachnoid hemorrhage.\n\nThe investigators hypothesize that a direct clamping strategy, combined with daily screening of standardized weanability criteria, will reduce the duration of external ventricular drain maintenance compared with the conventional gradual weaning strategy. SEVDVE-2 is a multicenter, randomized, controlled, parallel-group, single-blind superiority trial that will compare these two weaning strategies in 170 adult patients admitted to critical care for non-traumatic subarachnoid hemorrhage with a first external ventricular drain inserted within the previous 3 days. Patients will be randomized 1:1, stratified on the presence of an intraventricular hematoma. The primary outcome is the number of external ventricular drain-free days alive at Day 28.",[591,592,593,594],"Subarachnoid Hemorrhage","Hydrocephalus","Intracranial Hypertension","External Ventricular Drainage",[596,591,597,598,599,600,601,602],"External Ventricular Drain","Weaning; Hydrocephalus","Intracranial Pressure","Neurocritical Care","Direct Clamping","Gradual Weaning","Randomized Controlled Trial","2026-06-01",{"date":605,"type":45},"2026-06-05",{"date":74,"type":22},{"date":608,"type":22},"2031-10-01",{"name":51,"class":52},{"id":611,"slug":612,"hasResults":12,"nctId":613,"briefTitle":614,"officialTitle":615,"acronym":616,"eligibilityCriteria":617,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":618,"targetDuration":4,"studyType":23,"phases":620,"briefSummary":621,"conditions":622,"keywords":4,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":628,"lastUpdatePostDateStruct":629,"startDateStruct":631,"completionDateStruct":632,"leadSponsor":634,"locationsCount":635},"100607056","impact-of-infusion-line-change-frequency-on-infectious-complications-related-to-central-venous-catheters-in-the-icu---a-randomized-controlled-trial-100607056","NCT07183592","Impact of Infusion Line Change Frequency on Infectious Complications Related to Central Venous Catheters in the ICU - A Randomized Controlled Trial","Impact of Infusion Line Change Frequency on Infectious Complications Related to Central Venous Catheters in the Intensive Care Unit ICU","TANDOORI","Inclusion criteria\n\n* Adult patient\n* Any ICU patient with a central venous catheter (inserted by venipuncture) in place for less than 72 hours and with an expected dwell time of at least 7 days\n* Patient affiliated with or covered by a social security system\n* Patient who has given verbal consent or written consent from a third party or in the event that the patient is unable to give consent.\n\nExclusion Criteria\n\n* Patient with a documented bloodstream infection at the time of inclusion\n* Patient whose central venous catheter has been in place for more than 72 hours\n* Patient with suspected catheter-related infection\n* Patient whose study catheter was inserted using a guidewire exchange\n* Patient previously enrolled in the study during the same ICU stay\n* Patient whose condition, according to the clinician, does not allow safe placement of a central venous catheter, such as:\n\n  * Allergy to catheter material\n  * Confirmed deep vein thrombosis at the time of insertion\n  * Inflammatory skin disorder at the insertion site\n* Patient admitted for extensive burns\n* Inadequate understanding of the French language\n* Pregnant, breastfeeding, or postpartum woman\n* Person deprived of liberty by judicial or administrative decision\n* Person receiving involuntary psychiatric care\n* Person under legal guardianship or other legal protection measure",{"count":619,"type":22},2830,[25],"In the intensive care unit, patients' care and secure drugs administration require a central venous catheter. These invasive devices can lead to complications, particularly infections. Most preventive recommendations focus on catheter insertion, line handling, and dressings. Few recommendations adress catheter dwell time, which is certainly the main source of infection. Part of the prevention strategy is the regular and systematic replacement of infusion sets , as they may become contaminated during use, mainly through the hands of healthcare professionals. Prolonged use increases the risk of infection. Infusion lines changes involve disconnecting the old sets, discarding infusion devices containing drug residues, and replacing them with new sterile devices.\n\nCurrent international guidelines recommend replacing these sets every 4 days, and the Center for Disease Control and Prevention recommends not exceeding 7 days. Replacing these devices requires the time of qualified nurses, numerous sterile medical devices, and medications. In addition to the intended effect on infection prevention, the procedure has impacts on workload and costs.\n\nThe objective of the study is to demonstrate that changing infusion set every 7 days does not increase the rate of central venous catheters related infections compared with changing infusion set every 4 days.",[623,624,625,626,627],"Intensive Care (ICU)","Central Venous Catheter Related Infections","Critical Care Nursing","Catheter-associated Bloodstream Infections (CLABSI)","Nursing Workload","2026-05-12",{"date":630,"type":45},"2026-05-13",{"date":628,"type":45},{"date":633,"type":22},"2028-12",{"name":51,"class":52},27,""]